SCHEMBL936016

SCHEMBL936016

O=C(O)CNC(=O)c1ccc(O)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 2/20 0.69
KDM4E B2RXH2 2/20 0.69
MAPT P10636 2/20 0.69
SLC22A6 Q4U2R8 1/20 0.69
SLC22A8 Q8TCC7 1/20 0.69
CA1 P00915 4/20 0.61
CA2 P00918 4/20 0.61
GFER P55789 2/20 0.57
ATM Q13315 1/20 0.57
MPO P05164 1/20 0.57
CYP3A4 P08684 1/20 0.57
KDM5A P29375 1/20 0.57
BLM P54132 1/20 0.57
PMP22 Q01453 1/20 0.57
SOST Q9BQB4 1/20 0.53
MAPK1 P28482 2/20 0.51
ITGB3 P05106 1/20 0.51
ITGA2B P08514 1/20 0.51
PTPRC P08575 2/20 0.50
CA9 Q16790 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11175012 0.93 HIF1A (0.61) HIF1AKDM4EMAPTSLC22A6SLC22A8
Glycine SCHEMBL936464 0.93 HIF1A (0.66) HIF1AKDM4EMAPTSLC22A6SLC22A8
SCHEMBL13593287 0.93 HIF1A (0.61) HIF1AKDM4EMAPTSLC22A6SLC22A8
Hippuric Acid SCHEMBL8957458 0.92 HIF1A (0.59) HIF1AKDM4EMAPTSLC22A6SLC22A8
SCHEMBL11107537 0.91 KDM4E (0.80) HIF1AKDM4EMAPTSLC22A6SLC22A8
Benzoic Acid SCHEMBL15670619 0.89 HIF1A (0.57) HIF1AKDM4EMAPTSLC22A6SLC22A8
SCHEMBL24224263 0.85 KDM4E (0.71) HIF1AKDM4EMAPTSLC22A6SLC22A8
Hippuric Acid SCHEMBL7486 0.83 GAA (0.68) HIF1AKDM4EMAPTSLC22A6SLC22A8
SCHEMBL22030672 0.83 GAA (0.68) HIF1AKDM4EMAPTSLC22A6SLC22A8
Hippuric Acid SCHEMBL428479 0.83 GAA (0.68) HIF1AKDM4EMAPTSLC22A6SLC22A8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 336 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3869192-B1 METHOD FOR QUANTITATIVE DETECTION OF VARIOUS METABOLITES IN BIOLOGICAL SAMPLE HUMAN METABOLOMICS INST INC (CN) 2026-05-13 EP claimed
US-12584924-B2 Compositions and methods for diagnosing and treating chronic kidney disease SOCIETE DES PRODUITS NESTLE S.A. (CH) 2026-03-24 US claimed
US-20250258146-A1 QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP HUMAN METABOLOMICS INSTITUTE INC. (CN) 2025-08-14 US claimed
US-20250236901-A1 METHOD OF DETECTING A MICROORGANISM HAVING HIPPURICASE ACTIVITY BIOSYNTH AG (CH) 2025-07-24 US claimed
EP-4581047-A1 TOXIN-BINDER FOR HEMODIALYSIS Universität Hamburg (DE) 2025-07-09 EP claimed
WO-2025123045-A1 PREDICTIVE AND DIAGNOSTIC SCREENING METHODS FOR ENDOMETRIAL CANCER ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2025-06-12 WO claimed
US-12292445-B2 Methods of selecting subjects for treatment with metabolomic modulators THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-05-06 US claimed
EP-4511504-A1 METHOD OF DETECTING A MICROORGANISM HAVING HIPPURICASE ACTIVITY Biosynth AG (CH) 2025-02-26 EP claimed
US-20250051551-A1 IMPROVED POLYMER COMPOSITES WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) 2025-02-13 US claimed
CN-119291059-A Screening method for metabolic markers for distinguishing non-colorectal cancer diseases from colorectal cancer and application of screening method 哈尔滨脉图精准技术有限公司 2025-01-10 CN claimed
CN-104204798-A Biomarkers for bladder cancer and methods using the same METABOLON INC 2014-12-10 CN claimed
EP-2776832-A1 BIOMARKERS FOR BLADDER CANCER AND METHODS USING THE SAME Metabolon, Inc. (US) 2014-09-17 EP claimed
US-20140224737-A1 MOLECULARLY IMPRINTED POLYMERS FOR ELIMINATING METABOLITES FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH (DE) 2014-08-14 US claimed
WO-2013070839-A1 BIOMARKERS FOR BLADDER CANCER AND METHODS USING THE SAME METABOLON, INC. (US) 2013-05-16 WO claimed
US-20130011364-A1 MOLECULARLY IMPRINTED POLYMERS FOR ELIMINATING METABOLITES FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH (DE) 2013-01-10 US claimed
WO-2011010104-A1 METHODS IMPERIAL INNOVATIONS LIMITED (GB) 2011-01-27 WO claimed
WO-2011010103-A1 METHODS AND USES IMPERIAL INNOVATIONS LIMITED (GB) 2011-01-27 WO claimed
EP-0754760-B1 Method and reagent for detecting peroxidase or hydrogen peroxide YAMAGATA PUBLIC CORP DEV IND (JP) 2002-11-13 EP claimed
US-5780257-A PRODUCING PHENOXY RADICALS FROM P-SUBSTITUTED PHENOL COMPOUNDS, TRANSFERRING ELECTRONS FROM PHENOXY COMPOUND TO HYDROXY AMINE COMPOUND, MEASURING ELECTRON SPIN RESONANCE YAMAGATA TECHNOPOLIS FOUNDATION (JP) 1998-07-14 US claimed
EP-0754760-A1 Method and reagent for detecting peroxidase or hydrogen peroxide YAMAGATA TECHNOPOLIS FOUNDATION (JP) 1997-01-22 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12584924-B2 Compositions and methods for diagnosing and treating chronic kidney disease GLS, AADAT, FGF23 HIF1A 37/4885KDM4E 124/4885MAPT 3150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.